Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ExpreS2ion, Mucosis, and University of Copenhagen Receive Eurostars Grant

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
Eurostars™ grant for the pre-clinical development of an innovative placental malaria vaccine.

ExpreS2ion Biotechnologies and Mucosis, along with University of Copenhagen have announced that they have been awarded a Eurostars™ grant with a total budget of over €1 million for the pre-clinical development of an innovative placental malaria vaccine.

This collaboration will apply novel vaccine technologies developed at Mucosis and ExpreS2ion to a malaria antigen developed at University of Copenhagen in a project funded by The Danish National Advanced Technology Foundation.

This vaccine development program aims to provide women in high-risk areas lifelong protection against malaria infection.

Thomas Johnston, CEO of Mucosis, commented: "This Eurostars™ funded collaboration will leverage the strengths of our Mimopath mucosal vaccine platform in combination with the contributions of our two prestigious partners in a high-burden disease area. We see this opportunity as a further validation of our platform and its potential to combat the most difficult of infectious diseases."

Dr. Charlotte Dyring, CEO of ExpreS2ion, said: "We are excited that we have secured this grant and that we will be collaborating with Mucosis and their innovative vaccine delivery approaches, and with the team at UCPH that has discovered and progressed the new promising placental malaria vaccine antigen. This collaboration will allow us to apply glycosylation engineering to the ExpreS2 platform, thus widening the potential of this efficient platform for production of recombinant proteins. The consortium members have specific complementary know-how and expertise that ensure an efficient development path in addressing a substantial global health need."

Dr. Ali Salanti, Associate Professor University of Copenhagen, said: "Vaccines are one of the most efficient health interventions; however development of a malaria vaccine remains a substantial challenge. Furthermore, a malaria vaccine to protect pregnant women from malaria would ideally offer long lasting protection, and conventional vaccine methods so far do not deliver this. In this new collaboration we will have the opportunity to apply novel vaccine technologies developed at Mucosis and Expres2ion to our malaria vaccine antigen developed at University of Copenhagen, with the aim to develop such a vaccine that can offer women long term protection against malaria."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Mucosis Secures €3.7M from Wellcome Trust
Funding will enable new intranasal vaccine SynGEM® to be tested in phase I and IIa human clinical trials.
Thursday, January 21, 2016
Mucosis Receives Financial Support from the Dutch Government
Company receives an innovation credit line of up to €5 million for its SynGEM® program.
Friday, May 23, 2014
Mucosis Announces a Strategic Partnership with Changchun BCHT Biotechnology
Company raises EUR 5 million in a new financing round.
Wednesday, April 16, 2014
Mucosis Appoints Thomas Johnston to CEO
Mr. Johnston joined Mucosis as Chief Business Officer in May 2011, and succeeds Govert Schouten who is leaving the Company to found an internet start-up.
Monday, September 17, 2012
Mucosis Announces Positive Proof-Of-Concept Data for Mimopath® Platform in Humans
Mimopath®-based vaccines are able to produce balanced immune responses in both circulating blood and the respiratory tract.
Monday, May 14, 2012
Mucosis Announces Publication of Preclinical Data of Novel Influenza Vaccines
Mucosally administered Mimopath-based influenza vaccine protects against both homologous and heterologous challenge.
Thursday, May 03, 2012
Mucosis Announces New Scientific Advisory Board
Professors Jiri Mestecky, Willem van Eden and Peter J. Openshaw appointed to Scientific Advisory Board.
Friday, November 18, 2011
Mucosis Appoints Thomas Johnston as Chief Business Officer
Thomas Johnston will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Monday, June 06, 2011
Mucosis Appoints Thomas Johnston as Chief Business Officer
Thomas have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Wednesday, May 18, 2011
Scientific News
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!